News | August 10, 2024
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Dyslipidemia is a critical risk factor for cardiovascular diseases
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Subscribe To Our Newsletter & Stay Updated
